Download Chronotherapeutics

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Orphan drug wikipedia , lookup

Psychopharmacology wikipedia , lookup

Polysubstance dependence wikipedia , lookup

Compounding wikipedia , lookup

Bad Pharma wikipedia , lookup

Plateau principle wikipedia , lookup

Pharmacognosy wikipedia , lookup

Neuropsychopharmacology wikipedia , lookup

Theralizumab wikipedia , lookup

Pharmacogenomics wikipedia , lookup

Biosimilar wikipedia , lookup

Medication wikipedia , lookup

Neuropharmacology wikipedia , lookup

Drug design wikipedia , lookup

Prescription costs wikipedia , lookup

Prescription drug prices in the United States wikipedia , lookup

Pharmaceutical industry wikipedia , lookup

Drug interaction wikipedia , lookup

Drug discovery wikipedia , lookup

Pharmacokinetics wikipedia , lookup

Transcript
Chronotherapeutics
A biological rhythm is a self-sustaining process inside the human body. It is defined as the
process that occurs periodically in an organism in conjunction with and often in response to
periodic changes in environmental condition. Biological rhythm within a single day is termed as
circadian rhythm. Here, the oscillation time is 24 hours. Term Circadian is derived from the
Latin term circa meaning “about" and dies which is derived from "a day”. Also each term
indicating an oscillation period of time, an inherited master clock network composed of the
paired suprachiasmatic nuclei (SCN) controls circadian rhythms. These are placed in the
hypothalamus and the pineal gland of the human brain. Orchestration the period and phase of the
amplitude peripheral circadian clocks positioned in cells, tissues, and organ systems is called the
master clock.i
It refers to the clinical practice of harmonizing delivery of the drug in accordance with
body's circadian rhythm including ailment states to create maximum benefit and minimizing
harm. Biological rhythms at the cellular and sub cellular level can give rise to significant dosingtime differences in the pharmacodynamics of medications that are unrelated to their
pharmacokinetics. This phenomenon is termed chronesthesy. Rhythms in receptor number or
conformation, second messengers, metabolic pathways, or free-to-bound fraction of medications
help to explain this phenomenon. Chronotherapeutics is defined as a treatment system where the
in vivo drug availability has been timed in accordance to cyclic rhythms of drug related
biological phenomena to create maximum benefit minimizing harm. Important determinants in
chronotherapeutics include:

Chronopathology or disease pathophysiology

Period, amplitude, phase and level of the human circadian time structure to find out the
dose, drug-delivery pattern and administration time

Chronopharmacology including chronotoxicology, chronokinetics, chronoesthesy and
chronodynamics of drugs
1.1.1. Chronobiology
Chronobiology is the technical study of biologic rhythms and their fundamental mechanisms, so
it is the formal study of biological temporal rhythms like tidal, annual, seasonal, weekly and
daily rhythms. It was introduced into clinical as well as laboratory medicine in the 1950s for the
purpose of disease prevention. The term "Chrono" pertains to time and "Biology" is the science
of life, thus, chronobiology concerns with the observation of every metabolic event goes through
rhythmic changes in time that can be measured from seconds to seasons. Typical examples are
levels of plasma testosterone and cortisol, which typically peak in the early morning, and the
secretion of growth hormone, which peaks during sleep. Applying this science could help in
prevention and/or early diagnosis and treatment of diseases, and consequently, reduction in the
overall health care costs.ii
Table 1: The various measurements of biological rhythm
Period
Main rhythmic components
Short Period
s<τ<1 s
[τ<0.5 h]
Pulsatiles
τ~ min
Intermediate Period
Circadian (20 h< τ<28 h)
[0.5 h<τ<6 days]
Ultradian (0.5 h<τ <20 h)
Infradian (28 h <τ<6 days)
Long Period
Circamensual (τ~30 days)
[τ>6 days]
Circaseptan (τ~7 days)
Circamensual
Circannual (τ~1 year)
The circadian rhythm can further be broken down into routine cycles during the 24-hour day:[2]

Diurnal, which describes organisms active during daytime

Nocturnal, which describes organisms active in the night

Crepuscular, which describes animals primarily active during the dawn and dusk hours (ex:
white-tailed deer, some bats)
While circadian rhythms are defined as endogenously regulated, other biological cycles may be
regulated by exogenous signals. In some cases, multi-trophic systems may exhibit rhythms driven by
the circadian clock of one of the members (which may also be influenced or reset by external
factors). The endogenous plant cycles may regulate the activity of the bacterium by controlling
availability of plant-produced photosynthate.
Many other important cycles are also studied, including:

Infradian rhythms, which are cycles longer than a day, such as the annual migration or
reproduction cycles found in certain animals or the human menstrual cycle.

Ultradian rhythms, which are cycles shorter than 24 hours, such as the 90-minute REM cycle,
the 4-hour nasal cycle, or the 3-hour cycle of growth hormone production.

Tidal rhythms, commonly observed in marine life, which follow the roughly 12.4-hour transition
from high to low tide and back.

Lunar rhythms, which follow the lunar month (29.5 days). They are relevant e.g. for marine life,
as the level of the tides is modulated across the lunar cycle.

Gene oscillations – some genes are expressed more during certain hours of the day than during
other hours.
Figure 1: Human Circadian time structure
Chronopharmacology
Chronopharmacology is the examination of drug effects in the basis of biologic timing and
rhythm. In addition, it includes the study of the time-dependent dosing of pharmacologic agents.
Chronopharmacology also considers the particular chronobiotics, which are agents that can
control biologic rhythms. Chronopharmacokinetic studies have been reported for many drugs in
an attempt to explain chronopharmacological phenomena and demonstrate that the time of
administration is a possible factor in variation of the pharmacokinetics of a drug. Different
pharmacokinetics constraints of time like elimination rate, peak concentration, volume of
distribution, and AUC of a number of drugs are affected by circadian rhythms. Chronodynamics
relates to the dosing-time, which could be expressed as rhythm-dependent, under the divergences
in the effects of drugs. The variations in drug effect are associated with varying the time of
administration which attributed to the rhythms in the free-to-bound drug fraction, drug-specific
receptor numbers and conformations, rate limiting step(s) in metabolic pathways, and second
messenger and ion channel dynamics.iii
Historic perspective
Currently, three chronotherapeutic calcium channel blockers are available on the market for the
management of certain cardiovascular diseases when administered at bedtime, all 3 agents
provide a peak effect coinciding with the rise in blood pressure and heart rate in the critical time
period of 6:00 am to noon, and trough concentrations during sleep. Covera-HS®, Procardia XL®
(nifedipine) and Verelan PM® are some examples. FDA in 1998 approved Verelan PM®
(verapamil HCl), for hypertension, Schwarz Pharma marketed products, which was using the
chronotherapeutic oral drug absorption system (CODAS) technology, four to five hours delay in
drug delivery followed by an extended drug release is the technical feature in this. After the drug
is administered, peak concentrations arise after 11 hours with trough concentrations coming
around 4 hours post-dose. In 2003, FDA approved a unique graded extended release diltiazem
HCl tablets for the treatment of hypertension and angina with trade name Cardizem LA®. These
tablets made by compressed beads coated by polymer which giving lag time for appearance of
diltiazem in plasma around 3 hours and maximum plasma concentration between eleven to
eighteen hours after administration.iv
Affect of biological rhythm on cardiovascular diseases
A highly significant circadian variation was observed with many adverse cardiovascular events
in human body. It was concluded from 30 studies in 66,635 patients that timing of acute
myocardial infarction was definite. A forty percent increase in risk of myocardial infarction
between 6 am and noon was found. Also studies involving 19,390 patients found an increase in
sudden cardiac death by 29% during the early-morning hours, and increase in stroke risk by 49%
between 6 am and noon. The increased frequency of cardiovascular events in the early morning
is related to factors that activate increased myocardial oxygen demand and also in chorus to
reduction of oxygen supply. Blood pressure is not steady over a 24-hour period and also it is
fluctuating according to a circadian pattern. Lorgelly and colleagues (2003) stated that blood
pressure was soaring in the morning, with a rise at about 6 am and increasing further from 7 am.
Blood pressure reaching its lowest point around 3 am by gradual declination throughout the day
and especially during sleep, this is due to many factors like the time of awakening, an increase in
physical activity, serum cortisol level and catecholamine levels which all increases blood
pressure, heart rate and myocardial contractility. A pathophysiologic explanation for the
myocardial infarction, sudden cardiac death and angina pectoris in the early-morning hours is
explained by the above factors. Covera-HS® and Verelan-PM® are new chronotherapeutic
verapamil preparations recommended for dosing at night to provide higher drug levels in the
morning.v
i
. Dubal Ashwini; Karigar Asif. Chronotherapy: A novel drug delivery system, In: International
journal of research in ayurveda & pharmacy, 2 (6), 2011, 1691-1700.
ii
. Smolensky M.H., D'Alonzo G.E. Medical chronobiology: concepts and applications. Am Rev
Respir Dis: 147 (6 Pt 2), 1993, 2-19.
iii
. Reinberg A. New aspect of human chronopharmacology. Arch. Toxicol., 36, 1976, 327-339.
iv
. Smith D.H., Pharmacology of cardiovascular chronotherapeutic agents, Am. J. Hypertens.,
14:296, 2001, S-301S
v
. Sarasija S, Pathak S. Chronotherapeutics: emerging role of biorhythums in optimizing Drug
therapy Indian J Pharm Sci 2005;67(2):135-40